Halozyme Therapeutics (HALO) Current Assets (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Current Assets of $1.0 billion for Q1 2026, down 20.52% year-over-year from $1.3 billion in Q1 2025, and up 21.55% quarter-over-quarter from $825.2 million in Q4 2025.
Halozyme Therapeutics (HALO) Current Assets (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Current Assets for 17 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 20.52% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 20.52% YoY), while the FY2025 annual figure was $825.2 million, down 23.97% from the prior year.
- Current Assets improved to $1.0 billion in Q1 2026 per HALO's latest filing, from $825.2 million in the prior quarter.
- Across five years, Current Assets topped out at $1.3 billion in Q3 2025 and bottomed at $541.9 million in Q2 2022.
- Historically, Current Assets has averaged $914.4 million across 5 years, with a median of $879.0 million in 2023.
- Annual changes were most pronounced in 2022 — Current Assets slumped 45.79% — and 2024, when it jumped 45.41%.
- Halozyme Therapeutics' Current Assets stood at $739.0 million in 2022, then gained by 1.0% to $746.4 million in 2023, then surged by 45.41% to $1.1 billion in 2024, then decreased by 23.97% to $825.2 million in 2025, then gained by 21.55% to $1.0 billion in 2026.
- Business Quant data shows HALO's Current Assets at $1.0 billion in Q1 2026, $825.2 million in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 933.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 933.02 Mn |
| Mar 31, 2026 | 1.00 Bn |
| Dec 31, 2025 | 825.21 Mn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.12 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.13 Bn |
| Jun 30, 2024 | 987.80 Mn |
| Mar 31, 2024 | 873.58 Mn |
| Dec 31, 2023 | 746.42 Mn |
| Sep 30, 2023 | 879.01 Mn |
| Jun 30, 2023 | 765.75 Mn |
| Mar 31, 2023 | 615.02 Mn |
| Dec 31, 2022 | 739.01 Mn |
| Sep 30, 2022 | 653.20 Mn |
| Jun 30, 2022 | 541.94 Mn |
| Mar 31, 2022 | 988.69 Mn |
| Dec 31, 2021 | 926.29 Mn |
| Sep 30, 2021 | 1.02 Bn |